Tokyo Metropolitan Komagome Hospital in Japan Completes Installation of CyberKnife Robotic Radiosurgery System
“We are committed to offering patients the best technological innovations for cancer care and recognize that a dedicated stereotactic radiosurgery system capable of treating a broad range of tumors throughout the body would be a valuable addition to our center and an important new treatment option for our patients,” said Katsuyuki Karasawa, MD, PhD, director, Division of Radiation Oncology, Department of Radiology, Tokyo Metropolitan Komagome Hospital. “The CyberKnife System, with its strong foundation in clinical research and solid global reputation for quality, was the clear choice. We expect the technology to play a significant role in the non-invasive treatment of tumors at our hospital, especially those in the lung that are traditionally difficult to treat with radiation without undue harm to healthy tissue. We look forward to treating the first patients in the coming months.”
The CyberKnife System will enable physicians to offer both stereotactic radiosurgery and, Stereotactic Body Radiation Therapy (SBRT) as a treatment option for patients with tumors and non-cancerous lesions throughout the body, including intracranial, lung, head and neck, prostate and pancreatic tumors. The CyberKnife System delivers targeted and effective doses of radiation with a high level of accuracy, enabling treatment of tumors close to critical structures and healthy tissue. The CyberKnife System’s unique ability to not only track, but also automatically correct for movement of tumors in real time—such as the movement of lung tumors due to respiration—minimizes radiation exposure to healthy tissue and helps patients avoid many side effects typically associated with other radiation options.
"Japan has long been an early adopter of innovative medical technologies. In the three years since Shonin approval for use of the CyberKnife System to treat tumors in the body, we have seen growing interest in our technology throughout the country,” said Euan S. Thomson, Ph.D., president and CEO of Accuray. “One of the foremost cancer centers in Japan, Tokyo Metropolitan Komagome Hospital’s installation marks a significant milestone for Accuray as we continue to expand our global presence and bring the unique, personalized benefits of the CyberKnife System to patients around the world.”
Founded in 1879, Tokyo Metropolitan Komagome Hospital began treating patients with cancer and infectious diseases in 1975. Today, the Center has more than 800 beds and over 350,000 outpatients a year; the hospital is a full member of the Union for International Cancer Control (UICC).
Accuray received Shonin approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) to market the CyberKnife Robotic Radiosurgery System in 2010.
About
Accuray Incorporated (Nasdaq: ARAY), based in Sunnyvale, Calif., is the premier radiation oncology company that develops, manufactures and sells personalized innovative treatment solutions that set the standard of care, with the aim of helping patients live longer, better lives. The Company’s leading edge technologies – the CyberKnife and TomoTherapy Systems – are designed to deliver radiosurgery, stereotactic body radiation therapy, intensity modulated radiation therapy, image guided radiation therapy, and adaptive radiation therapy. To date, more than 300,000 patients worldwide have been treated using the Company's technologies and more than 616 systems have been installed in leading hospitals around the world. For more information, please visit www.accuray.com.
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, expansion of the Company’s global presence. Forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from expectations, including risks detailed from time to time under the heading "Risk Factors" in the Company’s report on Form 10-K for fiscal year 2011, and its reports on Form 10-Q for the first and second quarters of fiscal 2012
Forward-looking statements speak only as of the date the statements are made and are based on information available to the Company at the time those statements are made and/or management’s good faith belief as of that time with respect to future events. The Company assumes no obligation to update forward-looking statements to reflect actual performance or results, changes in assumptions or changes in other factors affecting forward-looking information, except to the extent required by applicable securities laws. Accordingly, investors should not place undue reliance on any forward-looking statements.
Contact:
Rebecca Phillips, Public Relations Manager, Accuray, +1-408-716-4773, rphillips@accuray.com; or Helen Shik of Schwartz MSL, +1-781-684-0770, Accuray@schwartzmsl.com